Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alison C Tree

Showing results (91-100 of 103) with videos related to

Pageof 11
Sort By:
Cancer Treatment Reviews|May 9, 2021
Salvage stereotactic body radiotherapy (SBRT) for intraprostatic relapse after prostate cancer radiotherapy: An ESTRO ACROP Delphi consensusBarbara A Jereczek-Fossa, Giulia Marvaso, Mattia Zaffaroni, et al.
The Lancet. Oncology|March 20, 2025
Hypofractionated radiotherapy for prostate cancer (HYDRA): an individual patient data meta-analysis of randomised trials in the MARCAP consortiumAmar U Kishan, Yilun Sun, Alison C Tree, et al.
International Journal of Radiation Oncology, Biology, Physics|January 3, 2023
Genomic Classifiers in Personalized Prostate Cancer Radiation Therapy Approaches: A Systematic Review and Future Perspectives Based on International ConsensusSimon K B Spohn, Cédric Draulans, Amar U Kishan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 21, 2022
Sequencing of Androgen-Deprivation Therapy of Short Duration With Radiotherapy for Nonmetastatic Prostate Cancer (SANDSTORM): A Pooled Analysis of 12 Randomized TrialsTing Martin Ma, Yilun Sun, Shawn Malone, et al.
Lancet (London, England)|May 19, 2024
Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trialChris C Parker, Noel W Clarke, Adrian D Cook, et al.
The Lancet. Oncology|May 2, 2024
Delphi consensus on stereotactic ablative radiotherapy for oligometastatic and oligoprogressive renal cell carcinoma-a European Society for Radiotherapy and Oncology study endorsed by the European Association of UrologyGiulia Marvaso, Barbara Alicja Jereczek-Fossa, Mattia Zaffaroni, et al.
Frontiers in Oncology|October 5, 2020
The MOMENTUM Study: An International Registry for the Evidence-Based Introduction of MR-Guided Adaptive TherapySophie R de Mol van Otterloo, John P Christodouleas, Erwin L A Blezer, et al.
JAMA Network Open|May 1, 2024
Safety and Tolerability of Online Adaptive High-Field Magnetic Resonance-Guided RadiotherapyJasmijn M Westerhoff, Lois A Daamen, John P Christodouleas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 28, 2023
Biochemical Recurrence Surrogacy for Clinical Outcomes After Radiotherapy for Adenocarcinoma of the ProstateSoumyajit Roy, Tahmineh Romero, Jeff M Michalski, et al.
European Urology|August 7, 2022
Local Failure Events in Prostate Cancer Treated with Radiotherapy: A Pooled Analysis of 18 Randomized Trials from the Meta-analysis of Randomized Trials in Cancer of the Prostate Consortium (LEVIATHAN)Ting Martin Ma, Fang-I Chu, Howard Sandler, et al.
Pageof 11

Showing results (91-100 of 103) with videos related to

Sort By:
Pageof 11
Cancer Treatment Reviews|May 9, 2021
Salvage stereotactic body radiotherapy (SBRT) for intraprostatic relapse after prostate cancer radiotherapy: An ESTRO ACROP Delphi consensusBarbara A Jereczek-Fossa, Giulia Marvaso, Mattia Zaffaroni, et al.
The Lancet. Oncology|March 20, 2025
Hypofractionated radiotherapy for prostate cancer (HYDRA): an individual patient data meta-analysis of randomised trials in the MARCAP consortiumAmar U Kishan, Yilun Sun, Alison C Tree, et al.
International Journal of Radiation Oncology, Biology, Physics|January 3, 2023
Genomic Classifiers in Personalized Prostate Cancer Radiation Therapy Approaches: A Systematic Review and Future Perspectives Based on International ConsensusSimon K B Spohn, Cédric Draulans, Amar U Kishan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 21, 2022
Sequencing of Androgen-Deprivation Therapy of Short Duration With Radiotherapy for Nonmetastatic Prostate Cancer (SANDSTORM): A Pooled Analysis of 12 Randomized TrialsTing Martin Ma, Yilun Sun, Shawn Malone, et al.
Lancet (London, England)|May 19, 2024
Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trialChris C Parker, Noel W Clarke, Adrian D Cook, et al.
The Lancet. Oncology|May 2, 2024
Delphi consensus on stereotactic ablative radiotherapy for oligometastatic and oligoprogressive renal cell carcinoma-a European Society for Radiotherapy and Oncology study endorsed by the European Association of UrologyGiulia Marvaso, Barbara Alicja Jereczek-Fossa, Mattia Zaffaroni, et al.
Frontiers in Oncology|October 5, 2020
The MOMENTUM Study: An International Registry for the Evidence-Based Introduction of MR-Guided Adaptive TherapySophie R de Mol van Otterloo, John P Christodouleas, Erwin L A Blezer, et al.
JAMA Network Open|May 1, 2024
Safety and Tolerability of Online Adaptive High-Field Magnetic Resonance-Guided RadiotherapyJasmijn M Westerhoff, Lois A Daamen, John P Christodouleas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 28, 2023
Biochemical Recurrence Surrogacy for Clinical Outcomes After Radiotherapy for Adenocarcinoma of the ProstateSoumyajit Roy, Tahmineh Romero, Jeff M Michalski, et al.
European Urology|August 7, 2022
Local Failure Events in Prostate Cancer Treated with Radiotherapy: A Pooled Analysis of 18 Randomized Trials from the Meta-analysis of Randomized Trials in Cancer of the Prostate Consortium (LEVIATHAN)Ting Martin Ma, Fang-I Chu, Howard Sandler, et al.
Pageof 11